Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104283 | 1.00 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL13833316 | 1.00 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL19325461 | 1.00 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL16695889 | 1.00 | ALDH1A1 (0.70) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Phosphoric Acid SCHEMBL441920 | 0.96 | ALDH1A1 (0.65) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Phosphoric Acid SCHEMBL7665465 | 0.96 | ALDH1A1 (0.65) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Triphosphate SCHEMBL6066340 | 0.91 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Zalcitabine SCHEMBL28057323 | 0.90 | LMNA (0.58) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL24082233 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL16552341 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAALBMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3495 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071254-A1 | POLYMERASE MEDIATED END MODIFICATION OF ABSEQ | BECTON DICKINSON CO (US) | 2026-03-12 | — | — | US | claimed |
| EP-4612322-A1 | POLYMERASE MEDIATED END MODIFICATION OF ABSEQ | Becton, Dickinson and Company (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250170228-A1 | TERMINALLY MODIFIED RNA | ARES CAPITAL CORPORATION, AS AGENT | 2025-05-29 | — | — | US | claimed |
| CN-120019159-A | Polymerase mediated ABSEQ terminal modification | 贝克顿迪金森公司 | 2025-05-16 | — | — | CN | claimed |
| US-12173365-B2 | Sequencing using non-natural nucleotides | ULTIMA GENOMICS, INC. (US) | 2024-12-24 | — | — | US | claimed |
| CN-119095964-A | Multi-tail and multi-cap mRNA and uses thereof | 博德研究所 | 2024-12-06 | — | — | CN | claimed |
| EP-4466074-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | The Broad Institute Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-20240277872-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-08-22 | — | — | US | claimed |
| WO-1989009055-A1 | ANTIVIRAL COMPOSITION CONTAINING AROMATIC POLYCYCLIC DIONES AND NUCLEOSIDE ANALOGS AND METHOD FOR TREATING RETROVIRUS INFECTIONS | NEW YORK UNIVERSITY (US) | 1989-10-05 | — | — | WO | claimed |
| US-4861759-A | Antiviral compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-08-29 | — | — | US | claimed |
| US-4835104-A | Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides | AJINOMOTO CO., INC., PATENT & LICENSING DEPARTMENT (JP) | 1989-05-30 | — | — | US | claimed |
| EP-0312222-A1 | Treatment of diseases caused by viruses | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1989-04-19 | — | — | EP | claimed |
| EP-0272007-A2 | 5- and 6- Succinimidyl - carboxylate isomers of rhodamine dyes | APPLIED BIOSYSTEMS, INC. (US) | 1988-06-22 | — | — | EP | claimed |
| EP-0270317-A2 | Pharmaceutical compositions for the treatment of diseases caused by viruses | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1988-06-08 | — | — | EP | claimed |
| US-4704357-A | TESTING DRUGS FOR EFFICARY AGAINST AIDS VIRUS | UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-11-03 | — | — | US | claimed |
| EP-0216510-A2 | Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1987-04-01 | — | — | EP | claimed |
| WO-1987001284-A1 | INHIBITION OF IN VITRO INFECTIVITY AND CYTOPATHIC EFFECT OF HTLV-III/LAV BY 2',3'-DIDEOXYNOSINE, 2',3'-DIDEOXYGUANOSINE, OR 2',3'-DIDEOXYADENOSINE | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1987-03-12 | — | — | WO | claimed |
| EP-0206497-A2 | Therapeutic nucleosides and their preparation | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-12-30 | — | — | EP | claimed |